Clonal Heterogeneity, Leukemic environment, ThErapy Resistance of chronic leukemias

Lymphome de Burkitt : définition, diagnostic et prise en charge thérapeutique actuelle

Morgane Gonin, Carolyne Croizier, Hedi Bensaber

Burkitt lymphoma is a rare and highly aggressive B-cell disorder characterized by rapid proliferation, and a translocation involving the c-MYC gene. It affects patients of all ages. The association with Epstein-Barr virus is well established in the 2022 World Health Organization classification, …

fr (code pays fourni par la source)

Identification of immunopeptides (pHLA) as candidate therapeutic targets in chondrosarcoma

Léa ROGUE, Jean‐Marc Monneuse, Céline Béchon, Lola Cepero et autres

Background: Chondrosarcoma (CHS) is the second most common primary malignant bone tumor and remains resistant to conventional therapies, underscoring the need to discover novel therapeutic targets. Cancer/testis antigens (CTAs), a class of tumor-associated proteins, represent attractive antigens for cancer immunotherapies such as …

fr (code pays fourni par la source)

Characterisation of the Novel HLA‐DPB1*04:01:116 Allele by Sequencing‐Based Typing

Lucie Blandin, Élodie Wojciechowski, Mamy Ralazamahaleo, Richard Lemal et autres

HLA-DPB1*04:01:116 differs from HLA-DPB1*04:01:01:01 by one nucleotide substitution in codon 43 in exon 2.

fr (code pays fourni par la source)

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study

Olivier Hermine, Orianne Debeaupuis, Gandhi Damaj, Johannes Lübke et autres

BACKGROUND: Systemic mastocytosis (SM) is a spectrum of hematologic disorders characterized by accumulation of atypical mast cells (MCs) in extracutaneous organs. SM with an associated hematologic neoplasm (SM-AHN), the most frequent subtype of advanced SM, is predominantly associated with myeloid neoplasms, consistent …

fr, de, ch, pl, se, ro, us, it, hu, tr, be, cz, at, nl, gr, no (code pays fourni par la source)

Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia – a study on behalf of the Chronic Malignancies Working Party of the EBMT

Joanna Ewa Drozd-Sokolowska, Luuk A. Gras, Laurien Baaij, Linda Koster et autres

Not available.

pl, nl, gb, de, us, no, se, fr, il, tr (code pays fourni par la source)

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

Roger G. Owen, H. McCarthy, Shirley D’Sa, Sheeba K. Thomas et autres

ABSTRACT: Acalabrutinib is a covalent Bruton tyrosine kinase inhibitor. In the phase 2 ACE-WM-001 trial, at 27.4-month median follow-up, acalabrutinib yielded durable responses in patients with treatment-naive (TN) or relapsed/refractory (R/R) Waldenström macroglobulinemia (WM). We report WM-001 results at 63.7-month median follow-up. …

gb, us, fr, nl, it, gr (code pays fourni par la source)

BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real‐life study

Urbain Tauveron-Jalenques, Luca Inchiappa, Jérôme Paillassa, Elsa Maître et autres

The datasets generated and analysed during the current study will be made available upon reasonable request to the corresponding author under reglementary conditions. Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied …

fr (code pays fourni par la source)

Characterisation of the Novel HLA‐C*05:315 Allele by Sequencing‐Based Typing

Lucie Blandin, Jonathan Visentin, Marine Cargou, Paul Rouzaire et autres

HLA-C*05:315 differs from HLA-C*05:01:01:02 by one nucleotide substitution in codon 304 in exon 5.

fr (code pays fourni par la source)

Rubrique « Actualités AMM » du journal Bulletin du Cancer : retour d’expérience des auteurs

Emma Ferber, Carolyne Croizier, Hedi Bensaber, Matthieu Delaye et autres

fr (code pays fourni par la source)

Characterisation of the Novel HLA‐B*35:08:18 Allele by Sequencing‐Based Typing

Lucie Blandin, Marine Cargou, Intissar Dalhoumi, Richard Lemal et autres

HLA-B*35:08:18 differs from HLA-B*35:08:01:01 by one nucleotide substitution in codon 284 in exon 5.

fr (code pays fourni par la source)

Les chimiothérapies ont-elles encore un avenir à l’ère de la médecine de précision ?

Philippe Pourquier, Nathalie Mazure, Stéphane Vignot, Jacques‐Olivier Bay

fr (code pays fourni par la source)

Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non‐inferiority sequential trial emulation

Maxime Beydon, Jérôme Stirnemann, Karima Yousfi, Samira Zebiche et autres

OBJECTIVE: To compare the efficacy and safety of extended interval (Q3-4W) enzyme replacement therapy (ERT) versus standard biweekly (Q2W) ERT in clinically stable type 1 Gaucher disease (GD) patients. METHODS: We emulated a target trial with a sequential trial design, using data …

fr, ch (code pays fourni par la source)